Abbott Laboratories (ABT)
NYSEHealth CareMedical - DevicesSnapshot 2026-10-30
NYSEHealth CareMedical - DevicesSnapshot 2026-10-30
Research Workspace
Put ABT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Adjusted EPS growth to about $5.48 per share in 2026: Direct metric needs a verified mapping.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskABT’s case rests on strong recent performance, with quarterly revenue growth rising from 7.8% to 14.5%. Management’s 2026 comparable-sales growth objective is 6%, though the latest earnings were inline. ABT trades at 20× P/E versus a 29× peer median. Expectations look modest versus our view, despite the company-specific 2026 sales-growth objective being threatened by guidance cuts. Our model puts the next-quarter miss probability near 22%. The primary adjusted-EPS growth pillar remains unverified, and peer multiples imply a price roughly in line with where it trades (about fair). The thesis is on watch.
Trailing returns as of 2026-10-30. ABT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering ABT (as of Oct 2026).
Based on 11 Wall Street analysts offering 12-month price targets for ABT in the last 4 months.
Continue this research
Compare ABT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ABT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put ABT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Deliver 2026 comparable sales growth of 6.0%
A guidance cut threatens the 2026 sales-growth objective and prompted a rating downgrade.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $106.20
The last 12 months of price, then the range of analyst 12-month targets from today’s $106.20.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Threatens: Deliver 2026 comparable sales growth of 6.0%
Lower sales guidance threatens the 2026 growth objective; analyst target cut reflects the outlook.

Settlement may impact financials and brand reputation.

Advances: Expand new product pipeline and regulatory approvals
FDA clearance supports new product pipeline expansion.

Legal settlement may impact financial resources and growth plans.

Settlement provides clarity and reduces legal risks.

Settlement improves financial position, supporting EPS growth.

Advances: Drive organic sales growth of 6.5% to 7.5% in 2026
Increased price target reflects confidence in growth potential.
